Advertisement

Topics

KOL Perspectives: Upadacitinib for Rheumatoid Arthritis [Report Updated: 01082018] Prices from USD $2500

08:57 EDT 16 Oct 2018 | BioPortfolio Report Blog

KOL Perspectives: Upadacitinib for Rheumatoid Arthritis


Summary


This KOL Insight briefing focuses on perceptions of novel upadacitinib data in RA.


The briefing includes analysis of KOL opinion on the following topic areas

Efficacy safety of upadacitinib in the SELECT COMPARE trial csDMARDIR patients

Efficacy safety of upadacitinib as a monotherapy in SELECT MONOTHERAPY trial MTXIR patients

Views on dose response for upadacitinib


Key Highlights


Majority of KOLs had a positive opinion of upadacitinib's efficacy, particularly vs. adalimumab, in the SELECT COMPARE trial

Most KOLs had a favorable opinion of Week 12 upadacitinib data vs. adalimumab from the SELECT COMPARE trial

KOLs appeared unsure of upadacitinib's comparative efficacy vs. other JAK inhibitors, with many citing the need for headtohead studies.


Scope


The insight briefing is based on Sociable Pharma's analysis of primary research with our RA key opinion leaders KOLs

In total, we conducted interviews with 10 KOLs: Five Europebased five USbased

Interviews performed in Q2 2018

KOL data is analyzed to produce: Charts summarizing KOL opinions

Chart callouts of key information details

KOL quotes

Summary of KOL reporting trends

Insight from Sociable Pharma's analysts.


Reasons to buy


Combines Qualitative semiquantitative insight from key opinion leaders on "Upadacitinib for Rheumatoid Arthritis"

Includes insight recommendations from our diseasespecific healthcare analysts

Utilizes independent expert viewpoints to validate the impact of new clinical data emerging trends on management of rheumatoid arthritis

Provides costeffective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Original Article: KOL Perspectives: Upadacitinib for Rheumatoid Arthritis [Report Updated: 01082018] Prices from USD $2500

NEXT ARTICLE

More From BioPortfolio on "KOL Perspectives: Upadacitinib for Rheumatoid Arthritis [Report Updated: 01082018] Prices from USD $2500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...